SQZ Biotechnologies
Watertown, US · Founded 2013 · Delaware corporation · 3 known investors
Founders & leadership
SQZ Biotechnologies was founded in 2013 by Robert S. Langer, Sc.D., Armon Sharei, Ph.D., and Armon Sharei.
RS
Robert S. Langer, Sc.D.Co-founder
AS
Armon Sharei, Ph.D.Co-founder
AS
Armon ShareiCo-founder
AW
Amy W. SchulmanExecutive
KE
Kris ElverumExecutive
HB
Howard BernsteinExecutive
AL
Agustin Lopez-MarquezExecutive
KF
Klavs F. Jensen, Ph.D.Named on SEC filing
Board
JF
Jonathan FlemingBoard director
EM
Eric MoessingerBoard director
MM
Mark Murcko, Ph.D.Board director
GA
Garry A. NicholsonBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$166.7M disclosed across 5 rounds · 2014–2019
▶$66.3MraisedJun 2020 · 27 investors · BiotechnologyRule 506(b)
▶$66.3MraisedJun 2020 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Howard Bernstein, M.D., Ph.D.Executive Officer
- Oliver Rosen, M.D.Executive Officer
- David FirstExecutive Officer
- Armon Sharei, Ph.D.Executive Officer, Director
- Eric MoessingerDirector
- Alexandra BalcomExecutive Officer
- Teri LoxamExecutive Officer
- Pushkal GargDirector
- Marc EliaDirector
- Zafrira AvnurDirector
- Lawrence KnopfExecutive Officer
- Klavs F. Jensen, Ph.D.Director
- Amy W. SchulmanDirector
- Jonathan FlemingDirector
- Offering amount
- $70.2M
- Amount sold
- $66.3M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$71.3MraisedNov 2019 · 48 investors · BiotechnologyRule 506(b)
▶$71.3MraisedNov 2019 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan FlemingDirector
- Armon Sharei, Ph.D.Executive Officer, Director
- Robert Langer, Sc.D.Director
- Klavs F. Jensen, Ph.D.Director
- Amy W. SchulmanDirector
- Pushkal GargDirector
- Eric MoessingerDirector
- Garry A. NicholsonDirector
- Marc EliaDirector
- Zafrira AvnurDirector
- Alex BalcomExecutive Officer
- Amount sold
- $71.3M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.1MraisedDec 2016 · 34 investors · BiotechnologyRule 506(b)
▶$24.1MraisedDec 2016 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amy W. SchulmanExecutive Officer, Director
- Mark Murcko, Ph.D.Director
- Kris ElverumExecutive Officer
- Garry A. NicholsonDirector
- Howard BernsteinExecutive Officer
- Robert S. Langer, Sc.D.Director
- Armon Sharei, Ph.D.Executive Officer, Director
- Jonathan FlemingDirector
- Eric MoessingerDirector
- Klavs F. Jensen, Ph.D.Director
- Offering amount
- $24.1M
- Amount sold
- $24.1M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$5.1MraisedJul 2015 · 24 investors · BiotechnologyRule 506(b)
▶$5.1MraisedJul 2015 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan FlemingDirector
- Klavs F. Jensen, Ph.D.Director
- Armon Sharei, Ph.D.Executive Officer, Director
- Robert Langer, Ph.D.Director
- Amy W. SchulmanDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$15KraisedApr 2014 · 1 investors · BiotechnologyRule 506(b)
▶$15KraisedApr 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LangerDirector
- Klavs JensenExecutive Officer, Director
- Agustin Lopez-MarquezExecutive Officer
- Armon ShareiExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $15K
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 9 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $253.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Science Foundation | Phase II | 2016 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $493.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $223.7K |
| National Science Foundation | Phase I | 2015 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded SQZ Biotechnologies?
- SQZ Biotechnologies was founded by Robert S. Langer, Sc.D., Armon Sharei, Ph.D., Armon Sharei in 2013.
- Who are SQZ Biotechnologies's investors?
- SQZ Biotechnologies's investors include Quark Venture Inc., Temasek, Veltro Argento.
- How much funding has SQZ Biotechnologies raised?
- SQZ Biotechnologies has disclosed $166.7M raised across 5 rounds.
- Where is SQZ Biotechnologies headquartered?
- SQZ Biotechnologies is headquartered in Watertown, US.